Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who Did Not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response

NCT00535847 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT00535847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00535847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who Did Not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
February 28, 2010
Enrollment
117 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c